key: cord-0865748-k2gkygzd
authors: Zeng, Lei; Wang, Meng-Di; Ming, Sheng-Li; Li, Guo-Li; Yu, Peng-Wei; Qi, Yan-Li; Jiang, Da-Wei; Yang, Guo-Yu; Wang, Jiang; Chu, Bei-Bei
title: An effective inactivant based on singlet oxygen-mediated lipid oxidation implicates a new paradigm for broad-spectrum antivirals
date: 2020-06-08
journal: Redox Biol
DOI: 10.1016/j.redox.2020.101601
sha: eacf1357d26ab849f60444cfb447530f85b56026
doc_id: 865748
cord_uid: k2gkygzd

Emerging viral pathogens cause substantial morbidity and pose a severe threat to health worldwide. However, a universal antiviral strategy for producing safe and immunogenic inactivated vaccines is lacking. Here, we report an antiviral strategy using the novel singlet oxygen ((1)O(2))-generating agent LJ002 to inactivate enveloped viruses and provide effective protection against viral infection. Our results demonstrated that LJ002 efficiently generated (1)O(2) in solution and living cells. Nevertheless, LJ002 exhibited no signs of acute toxicity in vitro or in vivo. The (1)O(2) produced by LJ002 oxidized lipids in the viral envelope and consequently destroyed the viral membrane structure, thus inhibiting the viral and cell membrane fusion necessary for infection. Moreover, the (1)O(2)-based inactivated pseudorabies virus (PRV) vaccine had no effect on the content of the viral surface proteins. Immunization of mice with LJ002-inactiviated PRV vaccine harboring comparable antigen induced more neutralizing antibody responses and efficient protection against PRV infection than conventional formalin-inactivated vaccine. Additionally, LJ002 inactivated a broad spectrum of enveloped viruses. Together, our results may provide a new paradigm of using broad-spectrum, highly effective inactivants functioning through (1)O(2)-mediated lipid oxidation for developing antivirals that target the viral membrane fusion process.

Introduction chemical inactivation methods. Unfortunately, a general method for producing safe 85 and immunogenic inactivated vaccines is lacking. Conventionally, formalin has been 86 extensively used to inactivate viruses in the manufacture of vaccines (12). However, 87 formalin treatment not only generates carbonyl groups on vaccine antigens, thus 88 inducing harmful and undesirable T helper type 2 biased immune responses (13), but 89 also causes structural damage to B-cell epitopes (14) and introduces carcinogenesis 90 (15). Owing to its drawbacks, research focus has shifted towards aziridin derivatives 91 acting on nucleic acids; these derivatives are highly reliable in inactivating various 92 DNA and RNA viruses. However, these aziridine derivatives are also highly toxic and PRV vaccine has no effect on the viral surface protein content and confers a stronger 132 neutralizing antibody response than conventional formalin-inactivated PRV vaccine, 133 thereby providing more efficient protection against lethal-dose PRV challenge. In 134 addition, the inactivation mediated by 1 we harvested the supernatants, filtered them through a 0.45 μm pore size filter, and 230 stored them at 4°C. Their infectivity was determined in parallel with a limiting 231 dilution assay, as described above. Images with a scan size of 1×1 μm 2 /4.5×4.5 μm 2 /20×20 μm 2 and resolution 512×512 335 pixels 2 were obtained with scan rates between 0.6 and 1.0 Hz and set points close to 417 To evaluate the capacity of LJ002 (Fig. 1A) for generating 1 O 2 , we added LJ002 

To examine a possible application of LJ002 in the control of viral diseases in as determined by fluorescence microscopy (Fig. 2E) , flow cytometry (Fig. 2F) , 447 immunoblotting ( Fig. 2G and 2H) , and TCID 50 (Fig. 2I and 2J) assays. These data 448 demonstrate that LJ002 treatment inhibits PRV infection. 450 To further characterize the molecular mechanism of LJ002's antiviral activity, we light for 1 h, and nearly 100% inhibition was achieved, thus suggesting that LJ002 can 463 directly inactivate these free virus particles and neutralize their infectivity. 464 We next determined the antiviral activity of LJ002 in controlling the spread of 465 established infections. PRV particles were allowed to first bind the PK-15 cell surface 466 at 4°C before the temperature was shifted to 37°C for 1 h to allow viral entry. The 467 inocula were then removed, and cells were incubated with or without the compound.

As shown in Fig. 3D , LJ002 was ineffective in limiting the growth of PRV.

Furthermore, mRNA expression results also indicated that addition of LJ002 after 470 viral entry did not affect the transcription of the immediate-early 180 gene ( Fig. 3E ; 471 IE180), early gene ( Fig. 3F; EP0) , and DNA replication-related gene ( Fig. 3G; UL5) . 478 To further demonstrate that LJ002 acts on the virus, we pretreated live PRV 495 Because viral membrane distortions were observed when cells were infected with 496 LJ002-inactivated PRV particles (Fig. 4F) , we sought to determine whether the virion 497 morphology might become deformed after LJ002 treatment. We first examined 498 untreated and treated virions by negative-stain electron microscopy. As shown in Fig.   499 5A, the viral envelope of untreated PRV virons was intact, whereas exposure to LJ002 500 led to disruption of the envelope and distortion of viral ultrastructure. The surfaces of 501 viruses exposed to 600 nM LJ002 appeared rougher, and their shapes appeared less 502 regular. The distortions in the membrane were more pronounced after 6 μM LJ002 phases, thereby indicating that the viral surface composition had changed (Fig. 5C ).

The heights of untreated virions were significantly greater than those of LJ002-treated 518 virions (Fig. 5D ). Higher magnification, and a three-dimensional (3D) view revealed 519 that exposure to LJ002 disrupted the envelope and caused indentations (arrows) in the 520 viral units (Fig. 5E) . Differences in the values of particle adsorption on mica are 521 associated with hydrophobic interactions between the particles and the surfaces (45).

The number of PRV particles adsorbed on mica whose surface was treated with the 523 aforementioned compound was significantly lower than that in the control group, thus 524 suggesting that the hydrophobicity of the viral surface had changed (Fig. 5F) . dose-dependent manner, as compared with the levels in the control group. In contrast, 535 the content of MDA did not increase after the administration of α-tocopherol (Fig. 6B) .

To explore whether LJ002 directly affected the lipid composition of viral membranes, 546 Because administration of the antioxidant resulted in 1 O 2 clearance and 547 decreased lipid oxidation, we next investigated the effects of α-tocopherol on 548 LJ002-induced viral membrane deformation and the antiviral activity of LJ002. By 549 comparing the AFM topography images obtained in the absence and presence of 550 α-tocopherol after 1 h of incubation with LJ002, we observed that the lipid envelope 551 of LJ002 treated PRV was considerably damaged, but these membrane deformations 552 were reverted by the addition of α-tocopherol, after which a smooth viral surface 553 comparable to that in the DMSO group was observed ( Fig. 7A and 7B) . Moreover, 554 α-tocopherol administration significantly attenuated the LJ002-induced reduction of 555 PRV particles adsorbed on mica, thereby supporting the notion that lipid oxidative 556 injury contributes to changes in the hydrophobicity of the viral surface (Fig. 7C) . With 557 increased concentrations of α-tocopherol, both the viral titer (Fig. 7D) and PRV-GFP 558 fluorescence assay results (Fig. 7E) showed that the addition of the 1 O 2 scavenger 559 reversed the antiviral activity of LJ002 against PRV. Together, our results confirm the 560 specific involvement of 1 O 2 in LJ002's destruction of the viral envelope and its 561 antiviral activity. 563 The potential toxicity of LJ002 was next assessed systematically. Growth of mice 564 was not affected by treatment with LJ002 in any of the doses assayed, on the basis of 565 body weight (Fig. 8A) and external appearance. None of the recipient mice died from 566 exposure to these LJ002 doses. Liver damage or hepatotoxicity in recipient mice was 567 analyzed by measurements of serum alanine aminotransferase (ALT) and aspartate 568 aminotransferase (AST) levels. As shown in Fig. 8B and 8C, the normal serum ALT 569 and AST levels following treatment indicated no significant liver damage caused by 5 570 mg/kg or 35 mg/kg per day of LJ002 treatment for 10 consecutive days. Moreover, in 571 a macroscopic analysis, none of the mice showed histomorphologic changes resulting 572 from LJ002 treatment. The toxicity to major organs was also investigated with H&E 573 staining. No appreciable abnormalities or noticeable organ damage was apparent in 574 any of the organs analyzed, regardless of experimental group (Fig. 8D) . These results 575 provide direct evidence that the prepared LJ002 has negligible tissue toxicity. 577 We next investigated the potential antiviral activity of LJ002 against PRV in vivo. 578 To define the virulence of PRV HN1201, we performed S.C. inoculation of 579 8-week-old mice with viral doses ranging from 2×10 1 to 2×10 6 TCID 50 . Infection with 580 2×10 6 TCID 50 PRV HN1201 induced 100% mortality by day 5 post injection; thus, the 581 infection progressed rapidly. Infection with 2×10 5 TCID 50 resulted in a survival rate of 582 90% (Fig 9A) . In mice lethally challenged with 2×10 6 TCID 50 of PRV HN1201, we 583 observed high mortality, and all mice died within 5 days post infection. In comparison, 584 mice infected with LJ002-inactivated PRV HN1201 showed 100% survival rate in 15 585 days observation (Fig. 9B) . Because PRV tends to infect neurons in the central 586 nervous system, we also examined viral proliferation in the brain tissue of the infected 587 mice (schematic outline in Fig. 9C ). Using an immunofluorescence staining method, 588 we found that the brain tissues of mice infected with PRV exhibited positive viral 589 antigen gB signals, whereas the DMEM (mock infection) group and the group 590 receiving LJ002-inactivated PRV showed negative viral signals (Fig. 9D and 9E ). Our 591 results demonstrated that PRV infection can be inhibited in vivo by pre-incubation 592 with LJ002. 633 Our studies showed that LJ002-mediated 1 O 2 oxidizes the viral membrane, NDV, and VSV showed undetectable GFP-expression and TCID 50 (Fig. 11A-11C ).

The HA titer also showed that 600 nM LJ002 pre-treatment inhibited H1N1 influenza 643 virus replication (Fig. 11D) . SeV exhibited a similar destructive efficiency with 600 644 nM of LJ002, and when LJ002 was increased to 6000 nM in the treatment, SeV was 645 completely inactivated according to the HA titer data (Fig. 11E) In mammals, enzymes such as myeloperoxidase have long been known to form virus vaccine preparation. We found that LJ002 was able to produce 1 O 2 , both in 661 solution and in living cells, which was quenched by antioxidants (Fig. 1) . Cellular 662 toxicity assays revealed that the cytotoxicity to cells was as high as 26.85 μM (IC50), 663 possibly because of the cells' powerful free radical scavenging system. At the 664 concentration of 600 nm, there was no effect on cell viability, number, and 665 morphology, but proliferation of PRV was significantly inhibited (Fig. 2) indicates that PRV might infect humans, thus underscoring the necessity of mandatory 677 PRV vaccination of swine and workers in the swine breeding industry. Therefore, we 678 used PRV as a model to evaluate the antiviral effect of LJ002 and its potential use in 679 animal husbandry. study, we demonstrated that LJ002 treatment caused a marked increase in the content 692 of MDA on both cells and purified PRV particles (Fig. 6) . Importantly, with 693 antioxidant treatment, the generation of lipid oxidation products was decreased, the 694 viral envelope was protected from damage, and viral infectivity was restored (Fig. 6,   695 7). Because LJ002 caused no substantial morphological changes in cells, we speculate 696 that its effects may be due to viral membranes derived from host cells lacking these 697 metabolic and repair pathways, thus leaving their static membranes susceptible to 698 LJ002 treatment.

Along with the high effectiveness of viral inactivation by LJ002, no signs of 700 adverse side effects were observed in the body weights, serum biochemical markers, 701 and histological examinations of the treated mice (Fig. 8) . The actual efficacy of 702 LJ002 in the prophylactic and immune protection of enveloped viral diseases is likely 703 to depend on viral inactivation as well as on the pathogenic profile of the virus. 704 Therefore, we conducted preliminary LJ002-mediated PRV inactivation efficacy 705 experiments in vivo through lethal challenge of mice immunized with PRV or 706 LJ002-inactivated PRV at the same TCID 50 . Encouragingly, LJ002 did show efficacy: 707 compared with the control group, the LJ002 treated group showed a 100% survival 708 rate, and no viral protein expression was observed in the mouse brain (Fig. 9) . (Fig. 11) .

According to our work, we speculate that LJ002-mediated 1 O 2 may be useful in 726 inactivating ASFV. ASFV is a large, enveloped, double-stranded DNA virus with five 727 layers: the genome-containing nucleoid (the first layer) is surrounded by a thick 728 protein layer (the second layer), which is wrapped with a lipid-bi-layer membrane (the 729 third layer) and an icosahedral protein capsid (the fourth layer); ASFV then buds 730 through the plasma membrane and gains an external envelope (the fifth layer) (9).

Recently, results have indicated that inactivated ASFV does not confer protection, 732 even in the presence of various adjuvants, thus suggesting that antibodies induced by challenge (56). Our results demonstrated that LJ002-mediated 1 O 2 can oxidize lipids 735 and destroy the membrane structure (Fig. 12) . Therefore, epitopes that are not easily 736 exposed and proteins that can elicit effective neutralizing antibodies or cell-mediated 737 immune responses may be exposed.

Considering all these factors, we believe that the LJ002-inactivated vaccine has 739 promise to be developed as a safe and efficacious vaccine against viral disease. 

Economic analysis and costing 758 of animal health: a literature review of methods and importance

Anthropogenic environmental change and the 761 emergence of infectious diseases in wildlife

Virus Neuropathogenesis and Associated Cytokine Expression

Endophthalmitis Caused By Pseudorabies Virus Infection

Pseudorabies virus variant in Bartha-K61-vaccinated pigs

Agricultural diseases on the move early in 771 the third millennium

African swine fever in the North 773

Caucasus region and the Russian Federation in years 2007-2012

Emergence of African Swine Fever in China

Architecture of African swine fever virus and implications for viral assembly

Changing Patterns of Emerging Zoonotic Diseases in Wildlife

Animals, and Humans Linked to Biodiversity Loss and Globalization

Veterinary vaccines for animal and public health

Influenza vaccines: recent advances in production technologies

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated 787 vaccines

A study of the effect of chemical inactivants on the 789 epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies

Formaldehyde carcinogenicity 792 research: 30 years and counting for mode of action, epidemiology, and cancer risk 793 assessment

Inactivation of viral antigens for vaccine preparation with particular 795 reference to the application of binary ethylenimine

Comparison of 797 different inactivation methods on the stability of Indian vaccine strains of foot and mouth 798 disease virus

Thermal inactivation of untreated and gamma-irradiated 800

A2-Aichi-2-68 influenza virus

Protein oxidative changes in whole 802 and skim milk after ultraviolet or fluorescent light exposure

Singlet oxygen stress in microorganisms

Singlet oxygen in plants: production, detoxification and 806 signaling

Role of lipid hydroperoxides in photo-oxidative stress signaling

Reactive electrophilic oxylipins: pattern recognition and signalling

Singlet molecular oxygen 814 regulates vascular tone and blood pressure in inflammation

Photosensitized singlet oxygen generation and detection: 816 Recent advances and future perspectives in cancer photodynamic therapy

Oxidation decomposition of 819 unsaturated fatty acids by singlet oxygen in phospholipid bilayer membranes

A broad-spectrum antiviral targeting entry of enveloped 825 viruses

A mechanistic paradigm for broad-spectrum antivirals that target 830 virus-cell fusion

Cell entry of enveloped viruses

Two classes of protective antibodies against Pseudorabies 834 virus variant glycoprotein B: Implications for vaccine design

Molecular cloning and 836 functional characterization of porcine cyclic GMP-AMP synthase

Maintenance of cyclic GMP-AMP homeostasis by ENPP1 is involved in pseudorabies virus 839 infection

Sequence of a Variant Pseudorabies Virus Strain Isolated in Central China

Antiviral Activity of

Porcine Interferon Regulatory Factor 1 against Swine Viruses in Cell Culture

A novel porcine reproductive and 848 respiratory syndrome virus vector system that stably expresses enhanced green fluorescent 849 protein as a separate transcription unit

Far-red fluorescence probe for monitoring 851 singlet oxygen during photodynamic therapy

Singlet oxygen 853 photosensitisation by the fluorescent probe Singlet Oxygen Sensor Green

A compilation of singlet oxygen yields from biologically 856 relevant molecules

A europium(III) complex as an efficient singlet oxygen 858 luminescence probe

Feasibility study on quantitative 860 measurements of singlet oxygen generation using singlet oxygen sensor green

Tocopherol as singlet oxygen 863 scavenger in photosystem II

Lycopene as the most efficient biological carotenoid 865 singlet oxygen quencher

Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use 868 glycosaminoglycans for entry

Limit Vibrational Spectroscopy and Morphological Analysis

Atomic force 873 microscopy imaging of DNA covalently immobilized on a functionalized mica substrate

Chemistry and biochemistry of 4-hydroxynonenal, 876 malonaldehyde and related aldehydes

Fast LC-MS/MS method for the determination of amphetamine, methamphetamine, MDA

Singlet oxygen production by biological systems

Sites of virus replication in the genital organs of boars inoculated 883 in the cavum vaginale with pseudorabies virus

Aujeszky's disease eradication in New Zealand

Infectious concerns of cross-species transplantation: xenozoonoses

Lipid peroxidation modifies the picture of membranes from the

Model" to the

Broad-spectrum antivirals against viral fusion

Influence of protein fold 892 stability on immunogenicity and its implications for vaccine design

LJ002-derived 1 O 2 oxidizes lipids in the viral envelope, thus inhibiting fusion between the virus and cell membrane

LJ002-inactivated PRV vaccine has no effect on the content of antigens on the viral surface

LJ002-inactivated PRV vaccine confers a stronger neutralizing antibody response than conventional formalin-inactivated vaccine